Proficio Capital Partners LLC Has $628,000 Stake in Danaher Co. (NYSE:DHR)

Proficio Capital Partners LLC lifted its stake in shares of Danaher Co. (NYSE:DHR) by 6.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,514 shares of the conglomerate’s stock after buying an additional 149 shares during the quarter. Proficio Capital Partners LLC’s holdings in Danaher were worth $628,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of DHR. Cape Investment Advisory Inc. bought a new position in shares of Danaher in the 4th quarter worth $25,000. Tsfg LLC lifted its holdings in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares in the last quarter. BKM Wealth Management LLC bought a new position in shares of Danaher in the 4th quarter worth $27,000. Wetzel Investment Advisors Inc. bought a new position in shares of Danaher in the 4th quarter worth $29,000. Finally, Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the 1st quarter worth $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on DHR. TD Cowen raised their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and raised their price objective for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Evercore ISI dropped their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Finally, Barclays raised their price objective on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $268.67.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the completion of the sale, the senior vice president now owns 29,830 shares in the company, valued at approximately $7,457,798.30. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the sale, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock valued at $37,536,717 in the last quarter. 10.90% of the stock is currently owned by corporate insiders.

Danaher Stock Performance

DHR traded down $0.83 during trading hours on Tuesday, hitting $239.82. The stock had a trading volume of 2,064,197 shares, compared to its average volume of 2,867,785. The company’s fifty day simple moving average is $255.15 and its 200 day simple moving average is $247.35. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $269.11. The stock has a market cap of $177.63 billion, a PE ratio of 40.65, a price-to-earnings-growth ratio of 3.66 and a beta of 0.83. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same quarter last year, the firm posted $2.36 EPS. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. Equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.